ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

YI vs CVS // ALTMAN Z-SCORE & DEBT/EQUITY

111 Inc. (NASDAQ) VS. CVS Health Corporation (NYSE) • 15-METRIC TALLY: YI 1 — CVS 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: YI
balance-sheet
3.34
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (YI VS. CVS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC YI CVS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 5.80% 45.00% -39.20 CVS /gross-margins <GO>
Return on Invested Capital (ROIC) -20.50% 2.60% -23.10 CVS /roic <GO>
EV/EBITDA & P/E Valuation — 25.7x — TIE /valuation <GO>
Free Cash Flow Yield — 6.76% — TIE /fcf-yield <GO>
Operating Margin 0.00% 1.20% -1.20 CVS /operating-margins <GO>
Net Profit Margin — 0.40% — TIE /net-margins <GO>
Revenue Growth (YoY) -9.00% 7.80% -16.80 CVS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.94% -2.94 CVS /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 3.34 2.31 +1.03 YI /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 CVS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.7 47.8 -6.10 CVS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.88 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 60.7x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $26.2M $115.53B -$115.50B CVS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR YI REV CVS REV YI GROSS % CVS GROSS % YI FCF CVS FCF
FY 2025 $1.80B $402.07B 5.8% 45.0% $16.4M $7.81B
FY 2024 $1.97B $372.81B 5.8% 44.7% $34.0M $6.33B
FY 2023 $2.11B $357.78B — — -$63.0M -$2.67B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
YI // BETA —
CVS // BETA 0.88